Anti-PD-1 for the treatment of advanced cutaneous squamous cell carcinoma in elderly patients: a French multicenter retrospective survey

Quentin Samaran1,2,11 · Romain Samaran3,4 · Ernestine Ferreira5 · Naeda Haddad6 · Antoine Fottorino7 · Hervé Maillard3 · Brigitte Dreno4 · Nicolas Meyer8 · David Azria9 · Eve Maubec6 · Caroline Gaudy-Marqueste7 · Nicolas Molinari10 · Pierre-Emmanuel Stoebner2 · Olivier Dereure1

Received: 4 July 2022 / Accepted: 1 August 2022 / Published online: 12 August 2022
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022

Abstract

Background Anti-PD1 agents are currently recommended as first-line treatment in advanced cutaneous squamous cell carcinoma (acSCC) by updated European guidelines. Although acSCC frequently affects elderly patients with multiple comorbidities, this subset of patients is often excluded of registration clinical trials.

Purpose To assess anti-PD-1 efficacy and safety in elderly acSCC patients in real-life conditions and describe this specific population with oncogeriatric evaluation tools.

Methods A multicenter retrospective study including acSCC patients at least 70 years old treated with PD-1 inhibitors was conducted in French referral centers. The primary endpoint was the overall response rate (ORR). Secondary endpoints included safety data, time to response (TTR), duration of response (DOR), overall survival (OS), and progression-free survival (PFS).

Results 63 patients were included. ORR was 57.1% (95% CI 44.0–69.5), median TTR and DOR were 3 and 5.5 months respectively. Median OS was not reached (95% CI 12.5 months-not reached) at data cut-off after a median follow-up of 8 months while median PFS was 8 months. (95% CI 5 months-not reached). Grade 3–5 adverse effects occurred in 47.6% of patients. 41.3% of patients experienced degradation of ECOG performance status during anti-PD-1 treatment. Nutritional state worsened in 27% of patients and 57.1% lost weight during treatment.

Conclusion In this particular subset of acSCC patients PD-1 inhibitors obtain results similar to those obtained in younger populations included in pivotal clinical trials, with acceptable safety. A specific oncogeriatric evaluation at treatment initiation and during follow-up appears important in this setting most notably to help manage toxicity.

Keywords Skin neoplasms (MeSH) · Immunotherapy (MeSH) · Aged (MeSH) · Cutaneous squamous cell carcinoma · Anti-PD-1

Introduction

Cutaneous squamous cell carcinoma (cSCC) is the second most frequent skin cancer in caucasians, with a steadily rising incidence over time (Que et al. 2018; Burton et al. 2016; Fitzmaurice et al. 1990). Despite its overall favorable clinical outcome when an adequate surgery is performed, it may progress to advanced stages (acSCC) in up to 5–20% of patients (Amaral et al. 2019), with locally advanced tumor (40%) no longer amenable to surgery or to radiation therapy, or with locoregional or distant secondary lesions (60%) (Soura et al. 2019; Hillen et al. 2018).

For several decades, surgery associated with adjuvant radiotherapy, platinum salts-based chemotherapies and epidermal growth factor (EGFR)-inhibiting agents have been the mainstays of therapeutic strategies in acSCC patients with limited clinical results, few sustained responses, significant toxicity especially for metastatic disease and finally a questionable benefit/risk ratio in the specific setting of elderly patients (Hillen et al. 2018; Maubec 2020; Leus et al. 2020; Cowey et al. 2020).
Updated 2020 European guidelines now recommend the use of anti-PD-1 agents as a first-line treatment in acSCC patients who are not candidates for curative surgery or curative radiation (Stratigos et al. 2020b) based on several pivotal clinical trials evaluating their efficacy and safety (Migden et al. 2018, 2020; Rischin et al. 2020; Grob et al. 2020; Maubec et al. 2020). However, although this specific population is particularly affected with acSCC, elderly and frail patients with an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 2 or more were often not included in these studies partly as a result of investigators’ decision related to the anticipation of serious side effects in these fragile patients.

To gain more accurate insights regarding the interest of PD-1 inhibitors in this specific population in real-life conditions, a multicenter retrospective assay was conducted in French referral centers with the aim to assess the benefit/risk ratio of these agents in acSCC elderly patients through specific oncogeriatric scores.

Materials and methods

Patients and collected data

Patients treated with a PD-1 inhibitor (cemiplimab, nivolumab, or pembrolizumab) for a histologically confirmed acSCC between January 1st, 2018 and May 15th, 2020 in seven French oncodermatological referral centers were retrospectively identified. Inclusions criteria were: age of 70 or more at treatment implementation; first perfusion carried out before January 16st, 2020; at least one follow-up evaluation after treatment introduction. Patients participating in industrial trials or concurrent academic study were not included. Data were retrospectively retrieved from computerized patients’ medical charts and submitted to anonymized analysis. The study was approved by the Institutional Review Board of the Montpellier University Hospital (notification number: IRB-MTP_2020_04_202000386).

Collected baseline data included: demographic parameters (age, gender, past profession), primary tumor data (date of diagnosis, location, diameter, histopathological features including maximal thickness and presence of perineural invasion), and treatments used before and after anti-PD-1 introduction. Three main acSCC subsets were defined: locally advanced cSCC (lacSCC), cSCC with regional progression only (rcSCC), and cSCC with distant metastasis (mcSCC).

Anti-PD-1 efficacy and safety endpoints

For each patient, tumor response to the anti-PD-1 agent was evaluated using clinical assessment [by the physician in charge] and/or imaging when applicable (according to Response Evaluation Criteria In Solid Tumors (RECIST1.0) criteria when possible). The Best Observed Response (BOR) was rated as complete (CR) or partial response (PR), stable disease (SD) or progressive disease (PD) as usually defined (Eisenhauer et al. 2009).

The primary endpoint was the Overall Response Rate (ORR; rate of CR or PR). Secondary endpoints included: Disease Control Rate (DCR; rate of CR, PR or SD), time to first observed response (TTR), duration of response (DOR) calculated from the first observed response to progression, death or data cutoff whatever event came first, progression-free survival (PFS) and overall survival (OS), calculated from treatment implementation until first progression, death from any cause or data cut-off whatever event came first, and safety data using the National Cancer Institute’s Common Terminology Criteria for Adverse Events (version 5.0) 2021 with a special attention to grade 3–5 Adverse Events (AE). DOR after anti-PD-1 discontinuation owing to protracted CR, high-quality PR or limiting toxicity until first progression, death, or data cutoff whatever event came first was also calculated.

Oncogeriatric parameters

To better evaluate the status of these elderly patients a number of validated oncogeriatric scores and indexes were used and applied to the population under scope:
- G8 score identifying elderly cancer patients (> 75 years old) requiring a specific geriatric assessment (Soubeyran et al. 2014) when a score of 14 or less is obtained.
- Lee’s prognostic index stratifying 50-year-old or older patients into a high-, intermediate-, and low-risk group for 4-year mortality (Lee et al. 2006), scores of 13 and 14 or more being associated with a 4-year risk of mortality of 59% and 64% respectively.
- Charlson comorbidity index rating associated disorders (Charlson et al. 1987), with a score of 7 or more being associated with an estimated 10 year survival of 0%.

Other oncogeriatric variables of interest in this population included: education level, nutritional state throughout the course of the treatment, associated morbid conditions (diabetes, immunodeficiency), functional disabilities like walking difficulties, number of drugs received at baseline, place of living, distance between the place of living and hospital, along with Activities of Daily Living (ADL)/Instrumental Activities of Daily Living (IADL) scores and Mini-Mental State Examination (MMSE).

Statistical analysis

Efficacy and safety analyses included all patients included in this study. For ORR and DCR, point estimates and 95%
CIs were assessed using the Clopper and Pearson exact binomial method. PFS and OS were calculated using the Kaplan–Meier method.

Exploratory univariable analysis investigating a possible relationship between ORR and several selected, possibly relevant parameters (age, gender, ECOG PS, disease status, unfavorable prognosis factors status (Stratigos et al. 2020a) (poorly or undifferentiated tumor, presence of perineural invasion, thickness > 6 mm, initial tumor size > 2 cm), PD-1 inhibitor, concurrent radiotherapy, immunodeficiency) was performed using a logistic regression model to estimate crude odds ratios (ORs). Multivariable analysis was planned for parameters reaching the level of statistical significance ($p \leq 0.05$) in univariable analysis.

**Results**

**Patients characteristics (data summarized in Tables 1, 2)**

A total of 63 patients were included, 51 male (81%), with a median age of 83 years (range: 70–102): 44.4% ($n = 28$) lacSCC, 36.5% ($n = 23$) rcSCC and 19.0% ($n = 12$) mcSCC. Primary tumor location was mostly head and neck (77.8%, $n = 49$) followed by limbs (17.5%, $n = 11$) and trunk (4.8%, $n = 3$).

**Anti-PD-1 regimen and subsequent treatments (data summarized in Table 2)**

Cemiplimab was the most used (82.5%, $n = 52$), followed by nivolumab (12.7%, $n = 8$), and pembrolizumab (4.8%, $n = 3$); all three molecules were used with either a fixed or a weight-adjusted dose. Only one patient received two different anti-PD-1 during the course of the disease (nivolumab followed by cemiplimab) and another one received the three molecules; in both cases, efficacy and tolerance of each anti-PD1 were separately assessed. Anti-PD-1 agents were used as first-line, second-line or third-line or beyond systemic treatment in 61.9% ($n = 39$), 22.2% ($n = 14$) and 15.9% ($n = 10$) of the patients respectively. Median anti-PD-1 treatment duration was 4.2 months (SD 4.1; range 0–17.3) at data cutoff. Median follow-up duration after first anti-PD-1 administration was 8.0 months (SD 5.4; range 1–28) at data cutoff.

Concurrent radiotherapy was used in 10 patients (15.9%) with a mean time of 8.0 days between PD-1 inhibitor implementation and first radiotherapy session. Only one of these 10 patients was treated with radiotherapy on two different occasions during the course of immunotherapy.

**Treatment efficacy (data summarized in Table 3)**

Regarding the primary endpoint, an objective response was observed in 36/63 patients with an ORR of 57.1% (95%CI 44.0–69.5). BOR was CR and PR in 12 (19.0%) and 24 (38.1%) patients respectively (Fig. 1). SD was observed in 7 additional patients (11.1%) with a DCR of 68.3% (95% CI 55.3–79.4). The response could not be properly evaluated in 3 patients (4.8%) owing to significant and fast degradation of general status (2 patient) or early treatment discontinuation related to severe AE occurrence after two infusions (1 patient).

Median TTR in responding patients was 3.0 months (SD 1.6; range 1–10) and median DOR at data cutoff was 5.5 months (SD 4.0; range 1–19). The DOR exceeded 6 months in 14 of 36 responding patients (38.9%). When PD-1 inhibitor was discontinued after protracted CR ($n = 9$) or high-quality PR ($n = 6$), median DOR after discontinuation was 5.0 months (SD 3.7; range 0.1–13.2) vs 6.7 months when treatment was permanently interrupted for limiting AEs after response achievement (SD 3.4; range 1.2–10.8).

Median PFS was 8 months (95% CI 5–not reached) with 6- and 12 month PFS rates of 56.6% (95% CI 45.0–71.2) and 44.3% (95% CI 31.3–62.7) respectively (Fig. 2A). Two patients were excluded of PFS analysis because of initial progression observed after two initial months of treatment but antiPD1 was maintained in both cases with secondary stable disease or sustained PR after a few months.

Median OS was not reached at data cut-off (95% CI 12.5–not reached) with 6- and 12 month OS rates of 75.2% (95% CI 64.9–87.0) and 65.8% (95% CI 54.0–80.2) respectively (Fig. 2B). 42 patients (66.7%) were alive at data cutoff of whom 22 (34.9%) were still receiving an PD-1 inhibitor. Patients flow charts are available as Appendices (Fig A1 and A2).

Regarding univariable analysis of predefined parameters possibly related to ORR, none of these characteristics reached the threshold of statistical significance (see Table A1 in Appendices) and subsequent multivariable analysis was thus not performed as a consequence.

**Safety**

55/63 patients (87.3%) experienced one or several AEs of any grade rated as possibly or probably related to immunotherapy (summarized in Table 4) including grade 3–5 AEs in 30 patients (47.6%), and 5 (7.9%) deaths. Specific safety data for each anti-PD-1 are reported in Appendices (Table A.2).
Table 1 | Patients and tumor characteristics at baseline of patients with advanced cutaneous squamous cell carcinoma treated with anti-PD-1

| Characteristics | lacSCC (n = 28) | rcSCC (n = 23) | mcSCC (n = 12) | Total (n = 63) |
|-----------------|----------------|----------------|----------------|----------------|
| Age             |                |                |                |                |
| Mean ± SD       | 83.5 ± 7.6     | 82.8 ± 6.9     | 80.8 ± 7.9     | 82.7 ± 7.5     |
| Median (range)  | 82.5 (70–102)  | 83 (72–95)     | 81.5 (70–97)   | 83 (70–102)    |
| Sex, N (%)      |                |                |                |                |
| Male            | 23 (82.1)      | 19 (82.6)      | 9 (75)         | 51 (81)        |
| Female          | 5 (17.9)       | 4 (17.4)       | 3 (25)         | 12 (19)        |
| ECOG PS score, N (%) |            |                |                |                |
| 0               | 5 (17.9)       | 1 (4.3)        | 2 (16.7)       | 8 (12.7)       |
| 1               | 12 (42.9)      | 12 (52.2)      | 6 (50)         | 30 (47.6)      |
| 2               | 5 (17.9)       | 6 (26.1)       | 4 (33.3)       | 15 (23.8)      |
| 3               | 5 (17.9)       | 3 (13)         | 0             | 8 (12.7)       |
| 4               | 1 (3.6)        | 1 (4.3)        | 0             | 2 (3.2)        |
| Immunosuppression, N (%) |              |                |                |                |
| No              | 23 (82.1)      | 19 (82.6)      | 11 (91.7)      | 53 (84.1)      |
| Yes             | 5 (17.9)       | 4 (17.4)       | 1 (8.3)        | 10 (15.9)      |
| Oncological/hematological diseases | 2 (7.1) | 4 (17.4) | 0 | 6 (9.5)  |
| Transplanted patients | 0 | 0 | 1 (8.3) | 1 (1.6) |
| Immunosuppressive therapies | 3 (10.7) | 0 | 0 | 3 (4.8) |
| Location, N (%) |                |                |                |                |
| Head/neck       | 27 (96.4)      | 16 (69.6)      | 6 (50)         | 49 (77.8)      |
| Temple/ear/lip area | 10 (35.7) | 9 (39.1) | 3 (25) | 22 (34.9) |
| Other           | 17 (60.7)      | 7 (30.4)       | 3 (25)         | 27 (42.9)      |
| Trunk           | 1 (3.6)        | 1 (4.3)        | 1 (8.3)        | 3 (4.8)        |
| Arm/leg         | 0              | 6 (26.1)       | 5 (41.7)       | 11 (17.5)      |
| Maximum diameter, N (%) |            |                |                |                |
| < 2 cm          | 6 (21.4)       | 6 (26.1)       | 3 (25)         | 15 (23.8)      |
| ≥ 2 cm          | 18 (64.3)      | 13 (56.5)      | 6 (50)         | 37 (58.7)      |
| Clark index, N (%) |            |                |                |                |
| < V             | 3 (10.7)       | 2 (8.7)        | 3 (25)         | 8 (12.7)       |
| V               | 18 (64.3)      | 19 (82.6)      | 5 (41.7)       | 42 (66.7)      |
| NE              | 7 (25)         | 2 (8.7)        | 4 (33.3)       | 13 (20.6)      |
| Tumor thickness, N (%) |            |                |                |                |
| < 6 mm          | 2 (7.1)        | 7 (30.4)       | 4 (33.3)       | 13 (20.6)      |
| ≥ 6 mm          | 11 (39.3)      | 5 (21.7)       | 4 (33.3)       | 20 (31.7)      |
| NE              | 15 (53.6)      | 11 (47.8)      | 4 (33.3)       | 30 (47.6)      |
| Tumor histologic differentiation, N (%) |            |                |                |                |
| Well or moderately differentiated | 24 (85.7) | 13 (56.5) | 7 (58.3) | 44 (69.8) |
| Poorly or undifferentiated | 2 (7.1) | 6 (26.1) | 3 (25) | 11 (17.5) |
| NE              | 2 (7.1)        | 4 (17.4)       | 2 (16.7)       | 8 (12.7)       |
| Desmoplasia, N (%) |            |                |                |                |
| 0               | 0              | 0              | 0              | 0              |
| Perineural invasion, N (%) |            |                |                |                |
| < 50%           | 3 (10.7)       | 1 (4.3)        | 1 (8.3)        | 5 (7.9)        |
| ≥ 50%           | 0              | 0              | 2 (16.7)       | 2 (3.2)        |
| NE              | 25 (89.3)      | 22 (95.7)      | 9 (75)         | 56 (88.9)      |

ECOG PS eastern Cooperative Oncology Group performance status, lacSCC locally advanced cutaneous squamous cell carcinoma, mcSCC advanced cutaneous squamous cell carcinoma with distant metastasis, NE not evaluated, rcSCC advanced cutaneous squamous cell carcinoma with regional progression only, SD standard deviation
### Table 2  Previous treatments, anti-PD-1 regimen and following treatments

| Characteristics                                                                 | lacSCC (n=28) | rcSCC (n=23) | mcSCC (n=12) | Total (n=63) |
|--------------------------------------------------------------------------------|---------------|--------------|--------------|--------------|
| **Number of treatments before the assessed anti-PD-1 initiation**              |               |              |              |              |
| Mean ± SD                                                                       | 1.4 ± 1.5     | 1.8 ± 1.0    | 2.4 ± 1.4    | 1.8 ± 1.4    |
| Median (range)                                                                  | 1 (0–5)       | 2 (1–5)      | 2 (1–6)      | 2 (0–6)      |
| **Treatments used before the assessed anti-PD-1, N (%)**                       |               |              |              |              |
| Surgery                                                                         | 15 (53.6%)    | 20 (87%)     | 12 (100%)    | 47 (74.6%)   |
| Radiotherapy                                                                    | 10 (35.7%)    | 4 (17.4%)    | 7 (58.3%)    | 21 (33.3%)   |
| Radiochemotherapy                                                               | 1 (3.6%)      | 1 (4.3%)     | 1 (8.3%)     | 3 (4.8%)     |
| Cetuximab                                                                       | 4 (14.3%)     | 7 (30.4%)    | 3 (25%)      | 14 (22.2%)   |
| Carboplatin and cetuximab                                                      | 3 (10.7%)     | 3 (13%)      | 2 (16.7%)    | 8 (12.7%)    |
| 5-FU, carboplatin, and cetuximab                                               | 1 (3.6%)      | 1 (4.3%)     | 1 (8.3%)     | 3 (4.8%)     |
| Paclitaxel and cetuximab                                                       | 2 (7.1%)      | 1 (4.3%)     | 0            | 3 (4.8%)     |
| Methotrexate                                                                    | 2 (7.1%)      | 0            | 0            | 2 (3.2%)     |
| Another PD-1 inhibitor (one or more)                                            | 1 (3.6%)      | 2 (8.7%)     | 1 (8.3%)     | 4 (6.3%)     |
| Gamma-knife                                                                    | 0             | 0            | 1 (8.3%)     | 1 (1.6%)     |
| Acitretin and nicotinamide                                                      | 1 (3.6%)      | 1 (4.3%)     | 0            | 2 (3.2%)     |
| Local treatment (topical 5-FU, DPT…)                                            | 0             | 1 (4.3%)     | 0            | 1 (1.6%)     |
| **Number of systemic treatments before the assessed anti-PD-1 initiation**      |               |              |              |              |
| Mean ± SD                                                                       | 1.5 ± 0.9     | 1.7 ± 0.9    | 1.8 ± 1.3    | 1.6 ± 1.0    |
| Median (range)                                                                  | 1 (1–4)       | 1 (1–4)      | 1 (1–5)      | 1 (1–5)      |
| **Time between first diagnosis and anti-PD-1 initiation, in years**            |               |              |              |              |
| Mean ± SD                                                                       | 1.8 ± 1.9     | 1.8 ± 1.4    | 2.7 ± 2.3    | 2.0 ± 1.9    |
| Median (range)                                                                  | 1.1 (0.1–7.4) | 1.1 (0.3–6.2)| 2.1 (0.4–8.6)| 1.1 (0.1–8.6)|
| **Anti-PD-1 regimen**                                                          |               |              |              |              |
| Cemiplimab                                                                      | 21 (75%)      | 20 (87%)     | 11 (91.7%)   | 52 (82.5%)   |
| 3 mg/kg every 2 weeks                                                           | 6 (21.4%)     | 7 (30.4%)    | 4 (33.3%)    | 17 (27%)     |
| 350 mg every 3 weeks                                                            | 14 (50%)      | 11 (47.8%)   | 6 (50%)      | 31 (49.2%)   |
| 3 mg/kg every 2 weeks and then 350 mg every 3 weeks                            | 1 (3.6%)      | 2 (8.7%)     | 1 (8.3%)     | 4 (6.3%)     |
| Nivolumab                                                                       | 5 (17.9%)     | 2 (8.7%)     | 1 (8.3%)     | 8 (12.7%)    |
| 3 mg/kg every 2 weeks                                                           | 2 (7.1%)      | 1 (4.3%)     | 0            | 3 (4.8%)     |
| 240 mg every 2 weeks                                                            | 2 (7.1%)      | 0            | 1 (8.3%)     | 3 (4.8%)     |
| 480 mg every 4 weeks                                                            | 1 (3.6%)      | 1 (4.3%)     | 0            | 2 (3.2%)     |
| Pembrolizumab                                                                   | 2 (7.1%)      | 1 (4.3%)     | 0            | 3 (4.8%)     |
| 2 mg/kg every 3 weeks                                                           | 2 (7.1%)      | 0            | 0            | 2 (3.2%)     |
| 200 mg every 3 weeks                                                            | 0             | 1 (4.3%)     | 0            | 1 (1.6%)     |
| **Concurrent radiotherapy**                                                     |               |              |              |              |
| No                                                                              | 26 (92.9%)    | 16 (69.6%)   | 11 (91.7%)   | 53 (84.1%)   |
| Yes                                                                             | 2 (7.1%)      | 7 (30.4%)    | 1 (8.3%)     | 10 (15.9%)   |
| **Number of treatments after the assessed anti-PD-1**                          |               |              |              |              |
| Mean ± SD                                                                       | 0.2 ± 0.7     | 0.3 ± 0.5    | 0.5 ± 1.2    | 0.3 ± 0.8    |
| Median (range)                                                                  | 0 (0–3)       | 0 (0–2)      | 0 (0–4)      | 0 (0–4)      |
| **Treatments used after immunotherapy, N (%)**                                  |               |              |              |              |
| Radiotherapy                                                                    | 2 (7.1%)      | 1 (4.3%)     | 1 (8.3%)     | 4 (6.3%)     |
| Cetuximab                                                                       | 2 (7.1%)      | 1 (4.3%)     | 1 (8.3%)     | 4 (6.3%)     |
| Carboplatin and cetuximab                                                      | 0             | 1 (4.3%)     | 1 (8.3%)     | 2 (3.2%)     |
| Paclitaxel and cetuximab                                                       | 1 (3.6%)      | 0            | 1 (8.3%)     | 2 (3.2%)     |
| Paclitaxel and carboplatin                                                      | 0             | 0            | 1 (8.3%)     | 1 (1.6%)     |
| Gemcitabine                                                                     | 0             | 0            | 1 (8.3%)     | 1 (1.6%)     |
| Another anti-PD1 (one or more)                                                 | 1 (3.6%)      | 2 (8.7%)     | 0            | 3 (4.8%)     |

lacSCC locally advanced cutaneous squamous cell carcinoma, mcSCC advanced cutaneous squamous cell carcinoma with distant metastasis, rcSCC advanced cutaneous squamous cell carcinoma with regional progression only, SD standard deviation.
The most frequently observed AEs were fatigue (34.9%, \(n = 22\)), anemia (23.8%, \(n = 15\)), weight loss (20.6%, \(n = 13\)), decreased lymphocyte count (17.5%, \(n = 11\)), and hypothyroidism (11.1%, \(n = 7\)). Deaths were caused by tumor bleeding (2), rectal bleeding (1), infectious pneumonitis (1) and multi-visceral sepsis (1).

AEs led to PD-1 inhibitor discontinuation in 18 patients (28.6%), but disease progression was an associated reason for interrupting treatment in 9 of these cases (14.3%).

Oncogeriatric evaluation (data summarized in Tables 5, 6)

G8 score was only scarcely evaluated at baseline (29.6%) and was \(\leq 14\) in most cases (77.8%). 38.1% of patients were submitted to a standard geriatric evaluation immediately before anti-PD-1 implementation. Lee prognostic score was thereby calculated at some time in most patients (68.3%) with a score of 13 or more in 60.5% while Charlson comorbidity index score was available for all patients with a score of 7 or more in a large majority (85.7%).

Interestingly, 41.3% of patients experienced degradation of ECOG PS score between the first and last PD-1 inhibitor infusion with a mean variation of 1 point while the nutritional state worsened in 27% of patients and 57.1% lost weight during treatment.

Discussion

Owing to encouraging results obtained with PD-1 inhibitors in advanced melanoma (Weber et al. 2015; Ribas et al. 2015) and the high tumor mutational burden (a putative biomarker of response to PD-1 inhibitors) identified in cSCC in general and likely related to dominant UV-driven oncogenesis, a beneficial effect of these molecules in acSCC was expected (Hall et al. 2020; Wu et al. 2020; Boussiotis 2016). Off-label use of nivolumab (Sellah et al. 2019; Blum et al. 2018) along with specific clinical trials investigating cemiplimab (Migden et al. 2018, 2020; Rischin et al. 2020) and pembrolizumab (Grob et al. 2020; Maubec et al. 2020) indeed reported the efficacy of these molecules in this setting compared to conventional chemotherapy and EGFR-inhibitors (Keeping et al. 2021). However, specific real-life data regarding efficacy and tolerance of anti-PD-1 in acSCC are currently scarce (Hanna et al. 2020; Salzmann et al. 2020; Shalhout et al. 2021; In et al. 2021; Valentin et al. 2021; Guillaume et al. 2021; Baggi et al. 2021), especially in elderly, fragile patients with poor ECOG performance status and often excluded of clinical trials as a consequence. Furthermore, it has been demonstrated that an older age was associated with worse OS (Xu et al. 2018).

Nonetheless, our survey clearly confirms that the results obtained with PD-1 inhibitors in this particular subset of acSCC patients are similar to those obtained in younger populations included in pivotal clinical trials, with acceptable safety. A synoptic comparison between this study and prior reports of anti-PD1 in acSCC (Migden et al. 2018, 2020; Rischin et al. 2020; Grob et al. 2020; Maubec et al. 2020; Hanna et al. 2020; Salzmann et al. 2020; Shalhout et al. 2021; In et al. 2021; Valentin et al. 2021; Guillaume et al. 2021; Baggi et al. 2021) is presented in Appendices (Table A.3).

As anticipated, the patients included in the present survey were older than in most previously published studies with a median age of 83 years, a majority of patients between 80 and 89 year-old at inclusion and about 20% of 90-year old and older patients. Of note, the median age of patients included in clinical trials (Migden et al. 2018, 2020; Rischin et al. 2020; Grob et al. 2020; Maubec et al. 2020) was between 71 to

---

**Table 3** Tumor response to PD-1 inhibitor (cemiplimab, nivolumab or pembrolizumab)

| Outcome                                | Total (\(n = 63\)) | lacSCC (\(n = 28\)) | rcSCC (\(n = 23\)) | mcSCC (\(n = 12\)) |
|----------------------------------------|--------------------|---------------------|--------------------|---------------------|
| **Best overall response, \(N(\%\)**   |                    |                     |                    |                     |
| Complete response                      | 12 (19)            | 5 (17.9)            | 3 (13.0)           | 4 (33.3)            |
| Partial response                       | 24 (38.1)          | 10 (35.7)           | 9 (39.1)           | 5 (41.7)            |
| Stable disease                         | 7 (11.1)           | 4 (14.3)            | 2 (8.7)            | 1 (8.3)             |
| Progressive disease                    | 17 (27.0)          | 8 (28.6)            | 7 (30.4)           | 2 (16.7)            |
| Not evaluable                          | 3 (4.8)            | 1 (3.6)             | 2 (8.7)            | 0                   |
| **Overall response rate, % (95% CI)** | 57.1 (44.0–69.5)   | 53.6 (33.9–72.5)    | 52.2 (30.6–73.2)   | 75.0 (42.8–94.5)    |
| **Disease control rate, % (95% CI)**  | 68.3 (55.3–79.4)   | 67.9 (47.6–84.1)    | 60.9 (38.5–80.3)   | 83.3 (51.6–97.9)    |

CI confidence interval, lacSCC locally advanced cutaneous squamous cell carcinoma, mcSCC advanced cutaneous squamous cell carcinoma with distant metastasis, rcSCC advanced cutaneous squamous cell carcinoma with regional progression only
83 years old (patients’ age ranged from 29 to 102 years old). Additionally, baseline ECOG PS score was at least 2 in 39.7% of this population and 15.9% suffered from immunosuppression, mainly related to onco/hematological diseases, while such patients were excluded in previously published prospective studies.

In our study, ORR was 57.1% with a CR rate of 19%, results slightly better than those obtained in prior trials. This difference might partly be explained by the concurrent use of radiotherapy in almost 16% of patients in the present study (a treatment not allowed in clinical trials) even though univariable analysis did not confirm a statistically significant association between the response and this treatment possibly owing to a lack of robustness. Of interest a study evaluating the efficacy of durvalumab, an anti-PD-L1, associated with chemoradiation is to be soon implemented (Lin et al. 2021). Conversely, the DOR and PFS were shorter than previously reported, which might be related to the absence of a priori selection of patients regarding general status with an immune response possibly declining over time as a consequence and/or to a higher frequency of limiting AEs in these fragile patients leading to more frequent premature treatment interruptions. This latter hypothesis is supported by the rate of grade 3 to 5 AEs observed in our study (47.6%), quite comparable to previous data obtained with cemiplimab (between 39.3 and 50.8%) but significantly higher than with pembrolizumab (between 6.7 and 7%, but only for treatment related AEs). These differences might also be explained by the increased risk of drug interactions owing to associated medications (Gambichler et al. 2022) and the possible overestimation of the liability of the anti-PD-1 agent in AE occurrence, which was not assessed by an independent committee in our study. Immunotherapy’s role in some of the AE reported in this study might hence be questionable, they might be linked to the natural evolution of the disease (e.g. tumor hemorrhage), or to the patients’ comorbidities (e.g. esophageal varices hemorrhage).

Fatigue, diarrhea, nausea, pruritus, and hypothyroidism were the most frequently reported AEs in acSCC treated with PD-1 inhibitors in previous studies and these events were similarly observed in our survey. Interestingly, weight loss and lymphocytes count decrease were not particularly notified as frequent AEs in prior reports and they might be more specifically observed in elderly patients. Of note, in this study as in the previously mentioned ones (Migden et al. 2018, 2020; Rischin et al. 2020; Grob et al. 2020; Maubec et al. 2020; Hanna et al. 2020; Salzmann et al. 2020; Shalhout et al. 2021; In et al. 2021; Valentin et al. 2021;
Fig. 2 Kaplan–Meier estimates of A progression-free survival and B overall survival (CI confidence interval, NR not reached)
the mandatory use of a specific geriatric initial staging and follow-up in elderly acSCC patients receiving an antineoplastic treatment, including anti-PD-1, to reassess the benefit/risk ratio on a regular basis.

Several specific strengths are to be emphasized in this survey: the significant number of patients included, comparable with most prior reports in real-life conditions (63 versus 18 to 76, with a mean number of patients of 36); a multicenter data collection in seven French cities with a likely relevant representativeness of acSCC patients; an accurate outcome assessment in all but three patients; the real-life conditions regarding patients’ characteristics, treatments, outcome, and side effects with the inclusion of elderly, fragile patients with heavy comorbidities usually excluded from most industrial trials while such patients are among the most likely ones to develop acSCC and to experience limiting side effects and perhaps less likely to respond to immunotherapy owing to possible immunosenescence (Daste et al. 2017); the use of specific geriatric tools, an assessment procedure not previously and specifically reported in immunotherapy-treated acSCC although highly relevant in these elderly patients who are likely to represent the majority of individuals treated with anti-PD-1 in a real-life setting.

**Table 4** Reported adverse effects according to National Cancer Institute’s Common Terminology Criteria Toxicity Grade that occurred in ≥ 5% of the 63 patients included during the course of the assessed anti-PD-1 treatment

| Adverse effect                           | Grade 1–2, N (%) | Grade 3, N (%) | Grade 4, N (%) | Grade 5, N (%) |
|------------------------------------------|-----------------|---------------|---------------|---------------|
| Fatigue                                  | 16 (25.4)       | 6 (9.5)       | 0             | 0             |
| Anemia                                   | 11 (17.5)       | 4 (6.3)       | 0             | 0             |
| Weight loss                              | 13 (20.6)       | 0             | 0             | 0             |
| Lymphocyte count decreased               | 6 (9.5)         | 5 (7.9)       | 0             | 0             |
| Hypothyroidism                           | 7 (11.1)        | 0             | 0             | 0             |
| Lung infection                           | 3 (4.8)         | 1 (1.6)       | 0             | 1 (1.6)       |
| GGT and/or alkaline phosphatase increased| 4 (6.3)         | 1 (1.6)       | 0             | 0             |
| Pruritus                                  | 5 (7.9)         | 0             | 0             | 0             |
| Eosinophilia                             | 5 (7.9)         | 0             | 0             | 0             |
| Creatinine increased                     | 5 (7.9)         | 0             | 0             | 0             |
| Tumor hemorrhage                         | 2 (3.2)         | 0             | 0             | 2 (3.2)       |
| Dry skin                                 | 3 (4.8)         | 1 (1.6)       | 0             | 0             |
| Eczema                                   | 4 (6.3)         | 0             | 0             | 0             |
| None or not confirmed                    | 8 (12.7)        |               |               |               |

NB: 1 patient who was treated with CEMIPLIMAB contracted a CoVID-19 infection. The grade of this infection was not evaluated.

GGT, gamma-glutamyl transferase.
Table 5  Patients treated with anti-PD-1 for advanced cutaneous squamous cell carcinoma: oncogeriatric data

| Characteristics, N (%) | lacSCC (n = 28) | rcSCC (n = 23) | mcSCC (n = 12) | Total (n = 63) |
|------------------------|----------------|---------------|---------------|---------------|
| **Age**                |                |               |               |               |
| < 80                   | 8 (28.6)       | 7 (30.4)      | 5 (41.7)      | 20 (31.7)     |
| 80–89                  | 14 (50)        | 11 (47.8)     | 5 (41.7)      | 30 (47.6)     |
| 90–99                  | 5 (17.9)       | 5 (21.7)      | 2 (16.7)      | 12 (19)       |
| ≥ 100                  | 1 (3.6)        | 0             | 0             | 1 (1.6)       |
| **G8 screening tool score** |            |               |               |               |
| > 14                   | 3 (10.7)       | 1 (4.3)       | 0             | 4 (6.3)       |
| ≤ 14                   | 6 (21.4)       | 5 (21.7)      | 3 (25)        | 14 (22.2)     |
| NE                     | 19 (67.9)      | 17 (73.9)     | 9 (75)        | 45 (71.4)     |
| **Standard geriatric evaluation before anti-PD-1 initiation** | | | | |
| No                     | 15 (53.6)      | 16 (69.6)     | 8 (66.7)      | 39 (61.9)     |
| Yes                    | 13 (46.4)      | 7 (30.4)      | 4 (33.3)      | 24 (38.1)     |
| ADL score              |                |               |               |               |
| < 3/6                  | 3 (10.7)       | 1 (4.3)       | 0             | 4 (6.3)       |
| ≥ 3/6                  | 15 (53.6)      | 11 (47.8)     | 5 (41.7)      | 31 (49.2)     |
| NE                     | 10 (35.7)      | 11 (47.8)     | 7 (58.3)      | 28 (44.4)     |
| IADL score             |                |               |               |               |
| < 4/8                  | 11 (39.3)      | 4 (17.4)      | 1 (8.3)       | 16 (25.4)     |
| ≥ 4/8                  | 5 (17.9)       | 8 (34.8)      | 4 (33.3)      | 17 (27)       |
| NE                     | 12 (42.9)      | 11 (47.8)     | 7 (58.3)      | 30 (47.6)     |
| MMSE score             |                |               |               |               |
| < 20/30                | 5 (17.9)       | 3 (13)        | 1 (8.3)       | 9 (14.3)      |
| ≥ 20/30                | 9 (32.1)       | 6 (26.1)      | 3 (25)        | 18 (28.6)     |
| NE                     | 14 (50)        | 14 (60.9)     | 8 (66.7)      | 36 (57.1)     |
| Education level        |                |               |               |               |
| ≤ 9 years of education | 8 (28.6)       | 8 (34.8)      | 5 (41.7)      | 21 (33.3)     |
| 10–12 years of education | 1 (3.6)    | 1 (4.3)       | 0             | 2 (3.2)       |
| University level       | 2 (7.1)        | 2 (8.7)       | 1 (8.3)       | 5 (7.9)       |
| Other level of education | 2 (7.1)     | 2 (8.7)       | 1 (8.3)       | 5 (7.9)       |
| NE                     | 15 (53.6)      | 10 (43.5)     | 5 (41.7)      | 30 (47.6)     |
| Lee prognostic index score |            |               |               |               |
| < 13                   | 9 (32.1)       | 4 (17.4)      | 4 (33.3)      | 17 (27)       |
| ≥ 13                   | 11 (39.3)      | 11 (47.8)     | 4 (33.3)      | 26 (41.3)     |
| NE                     | 8 (28.6)       | 8 (34.8)      | 4 (33.3)      | 20 (31.7)     |
| Charlson comorbidity index score | | | | |
| < 7                    | 8 (28.6)       | 1 (4.3)       | 0             | 9 (14.3)      |
| ≥ 7                    | 20 (71.4)      | 22 (95.7)     | 12 (100)      | 54 (85.7)     |
| Diabetes               |                |               |               |               |
| No                     | 21 (75)        | 19 (82.6)     | 10 (83.3)     | 50 (79.4)     |
| Yes                    | 7 (25)         | 4 (17.4)      | 2 (16.7)      | 13 (20.6)     |
| Yes, controlled without medication | 1 (3.6) | 1 (4.3)       | 0             | 2 (3.2)       |
| Yes, controlled with oral antidiabetic drugs only | 3 (10.7) | 1 (4.3)       | 0             | 4 (6.3)       |
| Yes, requiring insulin therapy | 3 (10.7) | 2 (8.7)       | 2 (16.7)      | 7 (11.1)      |
| Without end-organ damage | 1 (3.6) | 1 (4.3)       | 1 (8.3)       | 3 (4.8)       |
| With end-organ damage | 2 (7.1)        | 1 (4.3)       | 1 (8.3)       | 4 (6.3)       |
| **Malnutrition at anti-PD-1 initiation** | | | | |
| No                     | 20 (71.4)      | 13 (56.5)     | 8 (66.7)      | 41 (65.1)     |
| Moderate malnutrition | 6 (21.4)       | 6 (26.1)      | 2 (16.7)      | 14 (22.2)     |
| Severe malnutrition   | 2 (7.1)        | 4 (17.4)      | 2 (16.7)      | 8 (12.7)      |
Conversely, some limitations are to be acknowledged: the retrospective design limiting data comprehensiveness and homogeneity, especially regarding response evaluation often not based on standardized criteria like RECIST with possible reduced statistical robustness as a consequence; the lack of systematic evaluation of oncogeriatric parameters in all patients; the small number of patients receiving pembrolizumab and nivolumab, precluding a significant comparison of the different molecules; the use of heterogeneous, both body weight-adjusted and flat doses of anti-PD-1, even though pharmacokinetic data support an equivalent exposure to the molecule (Ogungbenro et al. 2018).

### Conclusion

This study clearly confirms the efficacy of anti-PD-1 agents to treat elderly acSCC patients in a real-life setting with no significant loss of efficiency compared to younger patients. Age should not be a limiting factor when prescribing immunotherapy anymore. However, AEs, including weight loss may have major consequences in these frail patients and must be closely monitored, especially by specific geriatric evaluation tools used at baseline and regularly throughout the course of treatment to ensure that it remains beneficial. The use of concurrent radiotherapy should be closer examined in larger studies.
Table 6  Deleterious effects of anti-PD-1 on elderly patients’ general health

| Characteristics, N (%) | Cemiplimab (n = 52) | Nivolumab (n = 8) | Pembrolizumab (n = 3) | Total (n = 63) |
|------------------------|---------------------|------------------|----------------------|---------------|
| Aggravation of ECOG PS score between first and last known anti-PD-1 administration |
| No                     | 32 (61.5)           | 3 (37.5)         | 2 (66.7)             | 37 (58.7)     |
| Yes                    | 20 (38.5)           | 5 (62.5)         | 1 (33.3)             | 26 (41.3)     |
| Malnutrition\(^a\) at the last known anti-PD-1 administration |
| No                     | 25 (48.1)           | 5 (62.5)         | 3 (100)              | 33 (52.4)     |
| Moderate malnutrition   | 13 (25.0)           | 2 (25)           | 0                    | 15 (23.8)     |
| Severe malnutrition     | 13 (25.0)           | 1 (12.5)         | 0                    | 14 (22.2)     |
| NE                     | 1 (1.9)             | 0                | 0                    | 1 (1.6)       |
| Worsening of nutritional state between first and last known anti-PD-1 administration |
| No                     | 35 (67.3)           | 7 (87.5)         | 3 (100)              | 45 (71.4)     |
| Yes                    | 16 (30.8)           | 1 (12.5)         | 0                    | 17 (27)       |
| NE                     | 1 (1.9)             | 0                | 0                    | 1 (1.6)       |
| Weight loss between first and last known anti-PD-1 administration |
| No                     | 19 (36.5)           | 4 (50)           | 2 (66.7)             | 25 (39.7)     |
| Yes                    | 31 (59.6)           | 4 (50)           | 1 (33.3)             | 36 (57.1)     |
| < 10%                  | 24 (46.2)           | 2 (25)           | 1 (33.3)             | 27 (42.9)     |
| 10–15%                 | 4 (7.7)             | 1 (12.5)         | 0                    | 5 (7.9)       |
| > 15%                  | 3 (5.8)             | 1 (12.5)         | 0                    | 4 (6.3)       |
| NE                     | 2 (3.8)             | 0                | 0                    | 2 (3.2)       |

ECOG PS eastern cooperative oncology group performance status, NE not evaluated

\(^a\)Malnutrition was defined based on BMI and/or serum albumin levels according to French guidelines (Haute Autorité de Santé, 2007). https://www.has-sante.fr/upload/docs/application/pdf/denutrition_personne_agee_2007_-_recommandations.pdf

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00432-022-04246-0.

Acknowledgements None.

Authors contribution QS: Conceptualization, data curation, formal analysis, investigation, methodology, Project administration, resources, supervision, visualization, writing—original draft, Writing—review & editing. RS:Data curation, investigation, resources, writing—review & editing: EF:Conceptualization, investigation, methodology, resources, visualization, writing—review & editing: NH:Investigation, resources, writing—review & editing: AF:Investigation, resources, writing—review & editing: HM:Investigation, resources, writing—review & editing: BD:investigation, resources, writing—review & editing: NM:Conceptualization, data curation, formal analysis, investigation, methodology, resources, visualization, writing—original draft, Writing—review & editing: CGM:Investigation, resources, writing—review & editing: PES:Investigation, resources, writing—review & editing: OD:Conceptualization, investigation, methodology, project administration, resources, supervision, writing—original draft, Writing—review & editing.

Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Availability of data and materials The data underlying this article are mainly available in the article and in its online supplementary material.

Complementary data will be shared on reasonable request to the corresponding author.

Declarations

Conflict of interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: David AZRIA: co-founder of NovaGray (outside the field of the present article): Olivier DEREREUR: investigator and/or consultant and/or member of advisory boards and/or speaker for: BMS, MSD, Sanofi Merck GmBH: Brigitte DRENO: investigator and/or consultant and/or advisory boards and/or speaker for: BMS, Regeneron, Merck: Caroline GAUDY MARQUESTE: speaker for BMS: Eve MAUBEC: consultant and/or advisory board; Sanofi, Novartis; research funding for AP-HP: MSD; Travel accommodations: Pierre Fabre, Sanofi, MSD; Nicolas MEYER: investigator and/or consultant and/or advisory boards and/or speaker for: BMS, MSD, Sanofi Merck GmBH: Nicolas MOLINARI: grants from GSK and Astra Zeneca, outside the submitted work. The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Ethical approval and consent to participate This study has been approved by the CHU de Montpellier Institut Review Board (IRB-MTP_2020_04_202000386). No patient refused to participate in this retrospective study after an information note was sent to all of them.

Consent for publication The patient pictured on Fig. 1 has given his written consent for publication of his photographs and associated data. No other patient is recognizable from the data presented in this article.
References

Amaral T, Osewold M, Presser D, Meiwes A, Garbe C, Leiter U (2019) Advanced cutaneous squamous cell carcinoma: real world data of patient profiles and treatment patterns. J Eur Acad Dermatol Venereol 33(Suppl 8):44–51

Baggi A, Quaglini P, Rubatto M et al (2021) Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma [published correction appears in Eur J Cancer. 2022 May; 166:309–310]. Eur J Cancer 157:250–258

Blum V, Müller B, Hofer S, Pardo E, Zeidler K, Diebold J et al (2018) Nivolumab for recurrent cutaneous squamous cell carcinoma: three cases. Eur J Dermatol 28(1):78–81

Boussiots VA (2016) Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med 375(18):1767–1788

Burton KA, Ashack KA, Khachemoune A (2016) cutaneous squamous cell carcinoma: a review of high-risk and metastatic disease. J Am Clin Dermatol 17(5):491–508

Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383

Cowey CL, Robert NJ, Espirito JL, Davies K, Frytak J, Lowy I et al (2020) Clinical outcomes among unresectable, locally advanced, and metastatic cutaneous squamous cell carcinoma patients treated with systemic therapy. Cancer Med 9(20):7381–7387

Daste A, Domblices C, Gross-Goupil M et al (2017) Immune checkpoint inhibitors and elderly people: a review. Eur J Cancer 82:155–216

Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247

Gambichler T, Scheel CH, Reuther J, Susok L (2022) Management of immune-related adverse events in anti-PD-1-treated patients with advanced cutaneous squamous cell carcinoma. J Eur Acad Dermatol Venereol 36(Suppl 1):23–28

Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F et al (1990) Global regional and national cancer incidence mortality years of life lost years lived with disability and disability adjusted life years for 29 cancer groups 1990 to 2017 a systematic analysis for the global burden of disease study. JAMA Oncol 5(12):1749–1768

Groß J-J, Gonzalez R, Basset-Seguin N, Vornicova O, Schachter J, Joshi A et al (2020) Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase ii trial (KEYNOTE-629). J Clin Oncol 38(25):2916–2925

Guillaume T, Puzenat E, Popescu D, Aubin F, Nardin C (2021) Cemiplimab-rcwlc in advanced cutaneous squamous cell carcinoma: real-world experience in a French dermatology department. Br J Dermatol 185(5):1056–1058

Hall ET, Fernandez-Lopez E, Silk AW, Dummer R, Bhatia S (2020) Immunopathologic characteristics of nonmelanoma skin cancers: implications for immunotherapy. Am Soc Clin Oncol Educ Book 40:1–10

Hanna GJ, Ruiz ES, LeBoeuf NR, Thakuria M, Schultms CD, Decaprio JA et al (2020) Real-world outcomes treating patients with advanced cutaneous squamous cell carcinoma with immune checkpoint inhibitors (CPI). Br J Cancer 123(10):1535–1542

Haute Autorité de Santé (2007) Stratégie de prise en charge en cas de dénutrition protéino-énergétique chez la personne âgée. https://www.has-sante.fr/upload/docs/application/pdf/denutrition_persone_agerage_2007_recommandations.pdf

Hillen U, Leiter U, Haase S, Kaufmann R, Becker J, Gutzmer R et al (2018) Advanced cutaneous squamous cell carcinoma: a retrospective analysis of patient profiles and treatment patterns—results of a non-interventional study of the DeCOG. Eur J Cancer 96:34–43

In GK, Vaidya P, Filkins A et al (2021) PD-1 inhibition therapy for advanced cutaneous squamous cell carcinoma: a retrospective analysis from the university of Southern California. J Cancer Res Clin Oncol 147(6):1803–1811

Keeping S, Xu Y, Chen C-I, Cope S, Mojebi A, Kuznik A et al (2021) Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma. Future Oncol 17(5):611–627

Lee SJ, Lindquist K, Segal MR, Covinsky KE (2006) Development and validation of a prognostic index for 4-year mortality in older adults. JAMA 295(7):801–808

Leus AJG, Frei M, Haisma MS, Terra JB, Plaat BEC, Steenbakkers RJHM et al (2020) Treatment of keratinocyte carcinoma in elderly patients—a review of the current literature. J Eur Acad Dermatol Venereol 34(9):1932–1943

Lin C, Ballah T, Nottage M et al (2021) A prospective study investigating the efficacy and toxicity of definitive chemoradiation and immunotherapy (CRIO) in locally and/or regionally advanced unresectable cutaneous squamous cell carcinoma. Radiat Oncol 16(1):69

Maubec E (2020) Update of the management of cutaneous squamous-cell carcinoma. Acta Derm Venereol 100(11):adv00143. https://doi.org/10.2340/00015555-3498

Maubec E, Boubaya M, Petrov P, Beylot-Barry M, Basset-Seguin N, Deschamps L et al (2020) Phase II study of pembrolizumab as first-line, single-drug therapy for patients with unresectable cutaneous squamous cell carcinomas. J Clin Oncol 38(26):3051–3061

Midgen MR, Rischin D, Schmids CD, Guminäi A, Hauschild A, Lewis KD et al (2018) PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med 379(4):341–351

Midgen MR, Khushalani NI, Chang ALS, Lewis KD, Schmids CD, Hernandez-Aya L et al (2020) Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol 21(2):294–305

National cancer institute’s common terminology criteria for adverse eventsAEs ([AE] version 5.0. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf).

Ogunbunwo K, Patel A, Duncombe R, Nuttall R, Clark J, Lorigan P (2018) Dose rationalization of pembrolizumab and nivolumab using pharmacokinetic modeling and simulation and cost analysis. Clin Pharmacol Ther 103(4):582–590

Que STK, Zwald FO, Schmids CD (2018) Cutaneous squamous cell carcinoma: incidence, risk factors, diagnosis, and staging. J Am Acad Dermatol 78(2):237–247

Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C et al (2015) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16(8):908–918

Rischin D, Midgen MR, Lim AM, Schmids CD, Khushalani NI, Hughes BGM et al (2020) Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. J Immunoother Cancer 8(1):e000775

Salzmann M, Leiter U, Loquai C, Zimmer L, Ugurel S, Gutzmer R et al (2020) Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study. Eur J Cancer 138:125–132

Sellah D, Saint-Jean M, Peuvrel L, Khammari A, Queéux G, Dréno B (2019) Anti-PD1 in Merkel cell carcinoma and cutaneous squamous cell carcinoma, description of five cases and recent data from the literature. J Eur Acad Dermatol Venereol 33(4):e159–e161

Shalhout SZ, Park JC, Emerick KS, Sullivan RJ, Kaufman HL, Miller DM (2021) Real-world assessment of response to anti-PD-1 therapy in advanced cutaneous squamous cell carcinoma
Soubeyran P, Bellera C, Goyard J, Heitz D, Curé H, Rousselot H et al (2014) Screening for vulnerability in older cancer patients: the ONCODAGE prospective multicenter cohort study. PLoS ONE 9(12):e115060

Soubeyran P, Bellera C, Goyard J, Heitz D, Curé H, Rousselot H et al (2014) Screening for vulnerability in older cancer patients: the ONCODAGE prospective multicenter cohort study. PLoS ONE 9(12):e115060

Stratigos AJ, Garbe C, Dessinioti C, Lebbe C, Bataille V, Bastholt L et al (2020a) European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: part 1. epidemiology, diagnostics and prevention. Eur J Cancer 128:60–82

Stratigos AJ, Garbe C, Dessinioti C, Lebbe C, Bataille V, Bastholt L et al (2020b) European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: part 2. Treatment Eur J Cancer 128:83–102

Valentin J, Gérard E, Ferte T et al (2021) Real world safety outcomes using cemiplimab for cutaneous squamous cell carcinoma. J Geriatr Oncol. S1879–4068(21):00052–7

Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16(4):375–384

Wu S, Slater NA, Sayed C, Googe PB (2020) PD-L1 and LAG-3 expression in advanced cutaneous squamous cell carcinomas. J Cutan Pathol 47(10):882–887

Xu MJ, Lazar AA, Garsa AA et al (2018) Major prognostic factors for recurrence and survival independent of the American joint committee on cancer eighth edition staging system in patients with cutaneous squamous cell carcinoma treated with multimodality therapy. Head Neck 40(7):1406–1414. https://doi.org/10.1002/hed.25114

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Authors and Affiliations

Quentin Samaran1,2,11 · Romain Samaran3,4 · Ernestine Ferreira5 · Naeda Haddad6 · Antoine Fottorino7 · Hervé Maillard8 · Brigitte Dreno4 · Nicolas Meyer8 · David Azria9 · Eve Maubec6 · Caroline Gaudy-Marqueste7 · Nicolas Molinari10 · Pierre-Emmanuel Stoebner2 · Olivier Dereure1

Romain Samaran
romainsamaran4@hotmail.com

Ernestine Ferreira
e-ferreira@chu-montpellier.fr

Naeda Haddad
naeda.haddad@aphp.fr

Antoine Fottorino
antoine.fottorino@ap-hm.fr

Hervé Maillard
hmaillard@ch-lemans.fr

Brigitte Dreno
brigitte.dreno@atlanmed.fr

Nicolas Meyer
meyer.n@chu-toulouse.fr

David Azria
david.azria@icm.unicancer.fr

Eve Maubec
eve.maubec@aphp.fr

Caroline Gaudy-Marqueste
caroline.gaudy@ap-hm.fr

Nicolas Molinari
nicolas.molinari@inserm.fr

Pierre-Emmanuel Stoebner
pierre.stoebner@chu-nimes.fr

Olivier Dereure
o-dereure@chu-montpellier.fr

1 Department of Dermatology, Montpellier University Hospital and Montpellier University, Montpellier, France
2 Department of Dermatology, Nîmes University Hospital and Montpellier University, Nîmes, France
3 Department of Dermatology, Le Mans Hospital, Le Mans, France
4 Department of Dermatology, Nantes University Hospital and Nantes University, Nantes, France
5 Department of Geriatrics, Montpellier University Hospital and Montpellier University, Montpellier, France
6 Department of Dermatology, Avicenne Hospital (AP-HP) and Paris 13 University, Bobigny, France
7 Department of Oncodermatology, La Timone Hospital (AP-HM) and Aix-Marseille University, Marseille, France
8 Institut Universitaire Du Cancer de Toulouse, Toulouse University Hospital, Toulouse, France
9 Fédération Universitaire d’Oncologie Radiothérapie, ICM—Institut Régional du Cancer Montpellier, Montpellier, France
10 IDESP, INSERM, Department of Statistics, Univ Montpellier, CHU Montpellier, Montpellier, France
11 Chru de Montpellier—Hôpital St Eloi—Service de Dermatologie, 80, Avenue Augustin Fliche, 34295 Montpellier Cedex 5, France